BR112014015101A8 - métodos para intensificar eficiência de etapas de cromatografia a jusante para purificação de anticorpos - Google Patents

métodos para intensificar eficiência de etapas de cromatografia a jusante para purificação de anticorpos

Info

Publication number
BR112014015101A8
BR112014015101A8 BR112014015101A BR112014015101A BR112014015101A8 BR 112014015101 A8 BR112014015101 A8 BR 112014015101A8 BR 112014015101 A BR112014015101 A BR 112014015101A BR 112014015101 A BR112014015101 A BR 112014015101A BR 112014015101 A8 BR112014015101 A8 BR 112014015101A8
Authority
BR
Brazil
Prior art keywords
polypeptide
membrane
interest
effluent
ion exchange
Prior art date
Application number
BR112014015101A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112014015101A2 (pt
Inventor
Michael Brown Arick
Ellen Thayer Brooke
John Dowd Christopher
Jospeh Bill Jerome
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47430154&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112014015101(A8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of BR112014015101A2 publication Critical patent/BR112014015101A2/pt
Publication of BR112014015101A8 publication Critical patent/BR112014015101A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
    • B01D15/361—Ion-exchange
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/165—Extraction; Separation; Purification by chromatography mixed-mode chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
  • Manufacture Of Macromolecular Shaped Articles (AREA)
BR112014015101A 2011-12-22 2012-12-18 métodos para intensificar eficiência de etapas de cromatografia a jusante para purificação de anticorpos BR112014015101A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161579285P 2011-12-22 2011-12-22
PCT/US2012/070373 WO2013096322A1 (en) 2011-12-22 2012-12-18 Ion exchange membrane chromatography

Publications (2)

Publication Number Publication Date
BR112014015101A2 BR112014015101A2 (pt) 2017-06-13
BR112014015101A8 true BR112014015101A8 (pt) 2021-06-08

Family

ID=47430154

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014015101A BR112014015101A8 (pt) 2011-12-22 2012-12-18 métodos para intensificar eficiência de etapas de cromatografia a jusante para purificação de anticorpos

Country Status (21)

Country Link
US (3) US10364268B2 (https=)
EP (2) EP2794635B8 (https=)
JP (5) JP6605202B2 (https=)
KR (3) KR102067075B1 (https=)
CN (2) CN108892706A (https=)
AR (1) AR089362A1 (https=)
AU (3) AU2012355356B2 (https=)
BR (1) BR112014015101A8 (https=)
CA (1) CA2859376C (https=)
ES (1) ES2697676T3 (https=)
HR (1) HRP20181846T1 (https=)
IL (2) IL267585B (https=)
MX (2) MX360453B (https=)
MY (1) MY172426A (https=)
PL (1) PL2794635T3 (https=)
RU (1) RU2648999C2 (https=)
SG (1) SG11201403437TA (https=)
SI (1) SI2794635T1 (https=)
TR (1) TR201815709T4 (https=)
WO (1) WO2013096322A1 (https=)
ZA (2) ZA201404593B (https=)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2648999C2 (ru) 2011-12-22 2018-03-29 Дженентек, Инк. Способы повышения эффективности этапов очистки белка, находящихся ниже по потоку, с использованием мембранной ионообменной хроматографии
WO2015088677A1 (en) 2013-12-12 2015-06-18 Emd Millipore Corporation Protein separations using an acrylamide containing filter
BR112016014824A2 (pt) 2013-12-27 2017-09-19 Chugai Pharmaceutical Co Ltd Método para purificar anticorpo que tem ponto isoelétrico baixo
CN104693303B (zh) * 2015-02-28 2018-03-13 苏州金盟生物技术有限公司 一种蛋白制品中的核酸去除方法
LT4209499T (lt) 2015-08-13 2024-11-25 Amgen Inc. Antigeną surišančių baltymų įkrautas giluminis filtravimas
GB201711481D0 (en) 2017-07-17 2017-08-30 Ucb Biopharma Sprl Protein purification
EP3546475A1 (en) * 2018-03-27 2019-10-02 Sanofi Full flow-through process for purifying recombinant proteins
US10792618B2 (en) 2018-06-19 2020-10-06 Sartorius Stedim Biotech Gmbh Particle separation and/or purification of a fluid
KR102140531B1 (ko) * 2018-08-07 2020-08-04 (주)휴온스 Gly-Tβ4의 제조방법
KR102893280B1 (ko) * 2018-08-14 2025-12-01 브리스톨-마이어스 스큅 컴퍼니 개선된 단백질 회수
GB201815405D0 (en) * 2018-09-21 2018-11-07 Fujifilm Mfg Europe Bv Membranes suitable for detecting, filtering and/or purifying biomolecules
WO2020128797A1 (en) * 2018-12-21 2020-06-25 3M Innovative Properties Company Method for testing a chromatography device used for ion exchange
AR119264A1 (es) * 2019-06-05 2021-12-09 Genentech Inc Método para reutilización de cromatografía
KR20220143676A (ko) * 2020-01-24 2022-10-25 엘커메스 파마 아일랜드 리미티드 정제 방법
US11416468B2 (en) * 2020-07-21 2022-08-16 International Business Machines Corporation Active-active system index management
CN116425826A (zh) * 2021-12-30 2023-07-14 广州百济神州生物制药有限公司 一种快速纯化质量样品的方法
CN116371011B (zh) * 2023-05-26 2023-08-18 湖南杰萃生物技术有限公司 一种从桑叶中提取黄酮和生物碱的方法
CN117866038B (zh) * 2024-03-11 2024-05-28 北京百力格生物科技有限公司 纯化含有宿主核酸的带亲和标签的酸性蛋白的方法

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE266710C (https=)
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
US4515893A (en) 1979-04-26 1985-05-07 Ortho Pharmaceutical Corporation Hybrid cell line for producing complement-fixing monoclonal antibody to human T cells
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
JPS6150925A (ja) 1984-08-17 1986-03-13 Toray Ind Inc 抗原または抗体の精製方法
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US5091178A (en) 1986-02-21 1992-02-25 Oncogen Tumor therapy with biologically active anti-tumor antibodies
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
EP0313343B2 (en) * 1987-10-23 2003-07-23 Schering Corporation Method of purifying protein
US5091313A (en) 1988-08-05 1992-02-25 Tanox Biosystems, Inc. Antigenic epitopes of IgE present on B cell but not basophil surface
US5720937A (en) 1988-01-12 1998-02-24 Genentech, Inc. In vivo tumor detection assay
EP0420937B1 (en) 1988-06-21 1994-11-09 Genentech, Inc. Therapeutic compositions for the treatment of myocardial infarction
AU632065B2 (en) 1988-09-23 1992-12-17 Novartis Vaccines And Diagnostics, Inc. Cell culture medium for enhanced cell growth, culture longevity and product expression
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
JP2844346B2 (ja) 1989-05-31 1999-01-06 昭 梶 新規ペプチドならびに新規ｄｎａ
EP0402226A1 (en) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Transformation vectors for yeast yarrowia
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
CA2113813C (en) 1991-08-14 2005-04-12 Paula M. Jardieu Immunoglobulin variants for specific fc epsilon receptors
DE69232137T2 (de) 1991-11-25 2002-05-29 Enzon Inc Multivalente antigen-bindende proteine
AU675929B2 (en) 1992-02-06 1997-02-27 Curis, Inc. Biosynthetic binding protein for cancer marker
WO1994004188A1 (en) 1992-08-21 1994-03-03 Genentech, Inc. Method for treating an lfa-1-mediated disorder
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5595721A (en) 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
DK0668877T3 (da) 1993-09-21 1999-09-13 Hemosol Inc Fortrængningschromatografisk fremgangsmåde og oprenset hæmoglobinprodukt
DK0733207T3 (da) 1993-12-10 1998-04-20 Genentech Inc Fremgangsmåder til diagnose af allergi og screening af anti-allergi-terapeutika
DK0739214T3 (da) 1994-01-18 1998-10-07 Genentech Inc Fremgangsmåde til behandling af parasitinfektionerunder anvendelse af IgE antagonister
US5702946A (en) 1994-03-03 1997-12-30 Genentech, Inc. Anti-IL-8 monoclonal antibodies for treatment of inflammatory disorders
US5534615A (en) 1994-04-25 1996-07-09 Genentech, Inc. Cardiac hypertrophy factor and uses therefor
IL117645A (en) 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
AU6267896A (en) 1995-06-07 1996-12-30 Imclone Systems Incorporated Antibody and antibody fragments for inhibiting the growth oftumors
IL125255A (en) 1996-01-23 2002-02-10 Genentech Inc Anti-cd18 antibodies for treating stroke
AU1458497A (en) 1996-01-31 1997-08-22 John Stephen Ayers Production of an immunoglobulin enriched fraction from whey protein solutions
US7147851B1 (en) 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
WO1998023761A1 (en) 1996-11-27 1998-06-04 Genentech, Inc. HUMANIZED ANTI-CD11a ANTIBODIES
JP3957765B2 (ja) 1997-04-07 2007-08-15 ジェネンテク・インコーポレイテッド 抗ｖｅｇｆ抗体
EP0981618B2 (en) 1997-05-15 2011-08-24 Genentech, Inc. Anti-apo-2 antibody
US6054293A (en) 1997-07-08 2000-04-25 The Regents Of The University Of California Semaphorin receptors
US6946129B1 (en) 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
CA2376596C (en) 1999-06-25 2009-10-06 Genentech, Inc. Humanized anti-erbb2 antibodies and treatment with anti-erbb2 antibodies
AU778199B2 (en) 1999-10-29 2004-11-25 Genentech Inc. Anti-prostate stem cell antigen (PSCA) antibody compositions and methods of use
EP1301591A4 (en) 2000-07-13 2004-05-26 Invitrogen Corp METHODS AND COMPOSITIONS FOR RAPID EXTRACTION AND ISOLATION OF PROTEINS AND PEPTIDES USING LYING MATRIX
UA83458C2 (uk) 2000-09-18 2008-07-25 Байоджен Айдек Ма Інк. Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf)
US7321026B2 (en) 2001-06-27 2008-01-22 Skytech Technology Limited Framework-patched immunoglobulins
CA2460819A1 (en) 2001-09-18 2003-03-27 Affinium Pharmaceuticals, Inc. Methods and apparatuses for purification
WO2003033656A2 (en) 2001-10-16 2003-04-24 Exelixis, Inc. MSREBPs AS MODIFIERS OF THE SREBP PATHWAY AND METHODS OF USE
EP1507793A4 (en) 2001-10-17 2006-02-01 Human Genome Sciences Inc NEUTROKIN ALPHA AND NEUTROKIN ALPHA SPLICE VERSION
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
KR101033196B1 (ko) 2002-02-14 2011-05-09 이뮤노메딕스, 인코오포레이티드 항-ｃｄ20 항체 및 그 융합 단백질 및 이들의 이용방법
CN101928344B (zh) 2002-10-17 2014-08-13 根马布股份公司 抗cd20的人单克隆抗体
EP3263596A1 (en) 2002-12-16 2018-01-03 Genentech, Inc. Immunoglobulin variants and uses thereof
CN1206240C (zh) * 2003-04-07 2005-06-15 中国科学院生态环境研究中心 高效离子交换膜色谱纯化卵黄蛋白原技术
CA2525251C (en) 2003-05-09 2015-10-27 Duke University Cd20-specific antibodies and methods employing same
AR044388A1 (es) 2003-05-20 2005-09-07 Applied Molecular Evolution Moleculas de union a cd20
US20050079184A1 (en) 2003-08-08 2005-04-14 Immunomedics, Inc. Bispecific antibodies for inducing apoptosis of tumor and diseased cells
US8147832B2 (en) 2003-08-14 2012-04-03 Merck Patent Gmbh CD20-binding polypeptide compositions and methods
US20080274501A1 (en) * 2007-05-02 2008-11-06 Chenming Zhang Method of purifying acidic proteins expressed in plants
US9433922B2 (en) 2007-08-14 2016-09-06 Emd Millipore Corporation Media for membrane ion exchange chromatography based on polymeric primary amines, sorption device containing that media, and chromatography scheme and purification method using the same
CA2703086C (en) 2007-10-26 2014-11-25 Asahi Kasei Chemicals Corporation Method for purifying protein
CN101889025B (zh) 2007-10-30 2013-11-13 健泰科生物技术公司 通过阳离子交换层析进行的抗体纯化
WO2009135656A1 (en) * 2008-05-06 2009-11-12 Lonza Biologics Plc. A method for the purification of antibodies using displacement chromatography
MX2011001506A (es) 2008-08-14 2011-03-15 Genentech Inc Metodos para eliminar un contaminante utilizado cromatografia de membrana de intercambio de ion en desplazamiento de proteina indigena.
GB0816242D0 (en) 2008-09-05 2008-10-15 Immunobiology Ltd Method of purifying protien complexes
MX346115B (es) 2009-08-06 2017-03-08 Genentech Inc * Metodo para mejorar la eliminación de virus en la purificacion proteica.
JP5787891B2 (ja) * 2009-09-01 2015-09-30 ジェネンテック， インコーポレイテッド 改変されたプロテインａ溶離による向上したタンパク質精製
CN102946906B (zh) * 2010-04-23 2015-07-15 弗·哈夫曼-拉罗切有限公司 生产异源多聚体蛋白质
EP4492053A3 (en) 2010-05-25 2025-03-19 F. Hoffmann-La Roche AG Methods of purifying polypeptides
JP2014534421A (ja) * 2011-10-03 2014-12-18 サッチェム，インコーポレイテッド 疎水性置換クロマトグラフィーのための中性双性イオン性置換剤分子
RU2648999C2 (ru) 2011-12-22 2018-03-29 Дженентек, Инк. Способы повышения эффективности этапов очистки белка, находящихся ниже по потоку, с использованием мембранной ионообменной хроматографии
WO2015198451A1 (ja) 2014-06-26 2015-12-30 楽天株式会社 情報処理装置、情報処理方法及び情報処理プログラム

Also Published As

Publication number Publication date
AU2020201070A1 (en) 2020-03-05
EP3492486A1 (en) 2019-06-05
JP2021169454A (ja) 2021-10-28
CN108892706A (zh) 2018-11-27
JP2020040952A (ja) 2020-03-19
JP7359807B2 (ja) 2023-10-11
CN104125963B (zh) 2018-08-17
HRP20181846T1 (hr) 2018-12-28
US10364268B2 (en) 2019-07-30
KR20200008022A (ko) 2020-01-22
ZA201404593B (en) 2022-12-21
IL233158B (en) 2019-07-31
AU2012355356B2 (en) 2017-10-12
JP6605202B2 (ja) 2019-11-13
US20240247027A1 (en) 2024-07-25
HK1203526A1 (en) 2015-10-30
ZA201903994B (en) 2023-12-20
PL2794635T3 (pl) 2019-02-28
US20140348845A1 (en) 2014-11-27
MX360453B (es) 2018-11-01
RU2014130017A (ru) 2016-02-10
US20200102346A1 (en) 2020-04-02
WO2013096322A1 (en) 2013-06-27
JP7402011B2 (ja) 2023-12-20
MY172426A (en) 2019-11-25
ES2697676T3 (es) 2019-01-25
IL267585A (en) 2019-08-29
AU2018200194B2 (en) 2019-11-14
WO2013096322A8 (en) 2014-02-27
RU2648999C2 (ru) 2018-03-29
AR089362A1 (es) 2014-08-20
EP2794635A1 (en) 2014-10-29
IL233158A0 (en) 2014-07-31
JP2015503524A (ja) 2015-02-02
CN104125963A (zh) 2014-10-29
AU2012355356A1 (en) 2014-07-10
TR201815709T4 (tr) 2018-11-21
JP2018109024A (ja) 2018-07-12
US11945837B2 (en) 2024-04-02
CA2859376C (en) 2022-04-19
BR112014015101A2 (pt) 2017-06-13
AU2018200194A1 (en) 2018-02-01
CA2859376A1 (en) 2013-06-27
JP2022101557A (ja) 2022-07-06
NZ626949A (en) 2016-11-25
EP2794635B8 (en) 2018-11-14
MX2014007622A (es) 2014-09-22
KR20140114834A (ko) 2014-09-29
KR102067075B1 (ko) 2020-01-17
KR20210025692A (ko) 2021-03-09
SI2794635T1 (sl) 2018-12-31
SG11201403437TA (en) 2014-07-30
MX2018013356A (es) 2020-09-14
WO2013096322A9 (en) 2013-08-22
EP2794635B1 (en) 2018-09-12
IL267585B (en) 2022-09-01

Similar Documents

Publication Publication Date Title
BR112014015101A8 (pt) métodos para intensificar eficiência de etapas de cromatografia a jusante para purificação de anticorpos
CY1122221T1 (el) Μεθοδοι αφαιρεσης ρυπου χρησιμοποιωντας ιοντοανταλλακτικη μεμβρανικη χρωματογραφια μετατοπισης γηγενων πρωτεϊνων
BR112012017124A2 (pt) método de modificação polipeptídica para purificação de multímeros polipeptídicos
RU2011137030A (ru) Способы очистки малых модулярных иммунофармацевтических белков
BR112015031196A2 (pt) “processo de purificação de anticorpo monoclonal”
BR112017018365A2 (pt) uso de lavagens alcalinas durante cromatografia para remoção de impurezas
ME02162B (me) Proces prečišćavanja proteina
JOP20180117B1 (ar) أجسام مضادة انتقائية لـ tau فائق المعالجة بفوسفوريلات وطرق لاستخدامها
BR112012009289B8 (pt) método para purificar um anticorpo anti-il-13 a partir de uma mistura de amostra que compreende um anticorpo anti-il-13 e pelo menos uma proteína de célula hospedeira (hcp)
BR112018075516A2 (pt) purificação de anticorpos multiespecíficos
RU2014111820A (ru) Способы элиминации вируса
BR112012004697B8 (pt) método para purificar um polipeptídeo compreendendo uma região ch2/ch3
AR072897A1 (es) Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c5
MA40510A (fr) Molécules bispécifiques de liaison à l'antigène activant les lymphocytes t
AR053632A1 (es) Metoddos para purificar anticuerpos anti a beta
EA201101593A1 (ru) КОМПОЗИЦИИ И СПОСОБЫ, ПРЕДНАЗНАЧЕННЫЕ ДЛЯ НАПРАВЛЕННОГО ВОЗДЕЙСТВИЯ АНТИТЕЛ НА БЕЛОК С3b СИСТЕМЫ КОМПЛЕМЕНТА
BR112013030628A2 (pt) "métodos para produção de uma proteína purificada de interesse utilizando uma matriz de cromatografia de afinidade (ca), e de um anticorpo purificado, fragmento de anticorpo ou proteína de fusão de fc utilizando a coluna de proteína a".
MX2017008410A (es) Reduccion selectiva de residuos cisteina en anticuerpos il-17.
BR112016013347A2 (pt) anticorpo monoclonal humano neutralizante anti-il-33
BR112012014937A2 (pt) solução de lavagem e método para cromatografia de afinidade
BR112013000623A2 (pt) purificação de proteína.
PE20150720A1 (es) Purificacion de iduronato-2-sulfatasa
BR112015017354A2 (pt) método para detectar pelo menos uma base modificada
EA201491575A1 (ru) Антитела к матриксной металлопротеиназе 9
EA200701452A1 (ru) Моноклональные антитела против подобного ангиопоэтину белка 4 (angptl 4)

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS.

B350 Update of information on the portal [chapter 15.35 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]